Vaxneuvance (15-valent pneumococcal conjugate vaccine) / Merck (MSD), Ligand - LARVOL DELTA

Cost-effectiveness analysis of routine pediatric vaccination of 15-valent pneumococcal conjugate vaccine in South Korea. (PubMed, Hum Vaccin Immunother) - "PCV15 was projected to provide a total savings of ₩36,213,756 [$27,751] with a gain of 2 QALYs versus PCV13. Under the model assumptions, switching from PCV13 to PCV15 is a cost-saving option for South Korea's routine pediatric pneumococcal vaccination program."

HEOR • Journal • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pediatrics • Pneumococcal Infections • Pneumonia

Predicting the Epidemiological Effects in the United Kingdom of Moving from PCV13 to PCV15 in the Routine Pediatric 1 + 1 Vaccination Schedule. (PubMed, Vaccines (Basel)) - "Switching from PCV13 to PCV15 for routine pediatric vaccinations under the 1 + 1 dosing schedule in the UK led to a lower IPD incidence in both the pediatric and overall populations."

Journal • Review • Infectious Disease • Pediatrics • Pneumococcal Infections

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=600 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1080 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=1080 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

V114 and Acute Otitis Media (V114-032/PNEU-ERA) (clinicaltrials.gov) - P3 | N=7000 | Active, not recruiting | Sponsor: Merck Sharp & Dohme LLC | Trial completion date: Jun 2025 ➔ Jan 2026 | Trial primary completion date: Jun 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Otorhinolaryngology

Economic evaluation of PCV21 in vaccine-naïve adults aged 19-64 years with underlying medical conditions in the United States. (PubMed, J Med Econ) - "The analysis indicated that the V116 strategy prevented a substantial number of cases and deaths compared to the PCV20 or PCV15 + PPSV23 strategies among vaccine-naive AR/HR adults aged 19-49 and 50-64 years...Deterministic and probabilistic sensitivity analyses confirmed the robustness of these findings, with over 95% of simulations yielding cost-saving results and all estimated ICERs remaining below $10,000/QALY gained. The findings suggest that the use of PCV21 (Capvaxive™) in adults aged 19-64 years with underlying medical conditions in the US can prevent a significant number of pneumococcal disease cases and deaths while demonstrating favorable economic outcomes across various scenarios."

HEOR • Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A dynamic transmission model for assessing the impact of pneumococcal vaccination in the United States. (PubMed, PLoS One) - "The calibrated model was then used to project the epidemiological impact of PCV15, a 15-valent pneumococcal vaccine, compared with the status quo vaccination with PCV13 and demonstrated the value of added serotypes in PCV15. Projections revealed that PCV15 would reduce IPD incidence by 6.04% (range: 6.01% to 6.06%) over 10 years when compared to PCV13."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

PCV13-Serotype Breakthrough Pneumococcal Disease in Infants Receiving High-Valency Conjugate Vaccines: Population-Level Modeling in France. (PubMed, Infect Dis Ther) - "Implementation of PCV15 in a 2 + 1 regimen could reduce bIPD incidence due to all PCV13 serotypes in infants, whereas PCV20 in a 2 + 1 regimen may lead to substantial increases in bIPD cases from PCV13 serotypes in infants. PCV20 in a 3 + 1 regimen could potentially lead to a resurgence of bIPD from PCV7 serotypes in infants."

Journal • Infectious Disease • Pneumococcal Infections

RATIONALE-15: Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 (clinicaltrials.gov) - P4 | N=106 | Recruiting | Sponsor: University of Oxford | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections • Pneumonia

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=900 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Measles • Mumps • Rubella • Varicella Zoster

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age. (PubMed, Vaccines (Basel)) - P3 | "Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults ≥50 years of age was immunogenic and well tolerated."

Journal • Infectious Disease • Novel Coronavirus Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=1840 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=600 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Varicella Zoster

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Recruiting | Sponsor: GlaxoSmithKline | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Varicella Zoster

Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398]. (PubMed, Vaccine) - No abstract available

Clinical • P3 data

Expanded Recommendations for Use of Pneumococcal Conjugate Vaccines Among Adults Aged ≥50 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2024. (PubMed, MMWR Morb Mortal Wkly Rep) - "Options included either 20-valent PCV (PCV20; Prevnar20; Wyeth Pharmaceuticals) or 21-valent PCV (PCV21; CAPVAXIVE; Merck Sharp & Dohme) alone or 15-valent PCV (PCV15; VAXNEUVANCE; Merck Sharp & Dohme) in series with 23-valent pneumococcal polysaccharide vaccine (PPSV23; Pneumovax23; Merck Sharp & Dohme)...Recommendations for PCVs among adults aged 19-49 years with risk conditions and PCV13-vaccinated adults have not changed from previous recommendations. This report summarizes evidence considered for these recommendations and provides updated clinical guidance for use of PCV."

Journal • Infectious Disease • Pneumococcal Infections

MISP 60528 Pneumococcal Vaccination (clinicaltrials.gov) - P=N/A | N=45 | Recruiting | Sponsor: Montefiore Medical Center | Trial completion date: Jul 2025 ➔ Jul 2026 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections • Transplantation

A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=1840 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Varicella Zoster

RATIONALE-15: Carriage to Assess Protection of New Pneumococcal Vaccines - PCV15 (clinicaltrials.gov) - P4 | N=106 | Not yet recruiting | Sponsor: University of Oxford

New P4 trial • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections • Pneumonia

A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age (clinicaltrials.gov) - P3 | N=750 | Not yet recruiting | Sponsor: GlaxoSmithKline

New P3 trial • Infectious Disease • Varicella Zoster

A phase III randomized study to evaluate the safety, tolerability and immunogenicity of V116, an adult-specific pneumococcal conjugate vaccine (PCV), followed by PCV15, in adults living with HIV (STRIDE-7) (HIV-Glasgow 2024) - P3 | "In adults living with HIV, V116 was well tolerated and induced comparable immune responses to PCV15 + PPSV23 for common serotypes and higher responses for V116-unique serotypes."

Clinical • P3 data • Human Immunodeficiency Virus • Infectious Disease • Pediatrics • Pneumococcal Infections • CD4

Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States. (PubMed, Infect Dis Ther) - "These results demonstrated that using V116 in adults aged ≥ 65 years in the US can prevent a substantial number of PD cases and deaths while remaining highly favorable economically over a wide range of inputs and scenarios."

Cost effectiveness • HEOR • Journal • CNS Disorders • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Public Health Impact and Cost-Effectiveness of Replacing PCV13 With PCV15 in the National Immunization Program in Saudi Arabia (ISPOR-EU 2024) - "Including PCV15 in Saudi Arabian NIP can prevent a significant number of pneumococcal cases and deaths. PCV15 further offers value as a highly cost-effective immunization strategy compared to PCV13 both from payer and societal perspectives."

Cost effectiveness • HEOR • CNS Disorders • Infectious Disease • Otorhinolaryngology • Pneumococcal Infections • Pneumonia • Respiratory Diseases